Department of Immunology, Genetics and Pathology, Genomics and Neurobiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Department of Immunology, Genetics and Pathology, Genomics and Neurobiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Centre for Women's Mental Health during the Reproductive Lifespan - Womher, Uppsala University, Uppsala, Sweden.
Thromb Res. 2023 Aug;228:151-162. doi: 10.1016/j.thromres.2023.06.011. Epub 2023 Jun 10.
Deep vein thrombosis (DVT) is a complex disease, where 60 % of risk is due to genetic factors, such as the Factor V Leiden (FVL) variant. DVT is either asymptomatic or manifests with unspecific symptoms and, if left untreated, DVT leads to severe complications. The impact is dramatic and currently, there is still a research gap in DVT prevention. We characterized the genetic contribution and stratified individuals based on genetic makeup to evaluate if it favorably impacts risk prediction.
In the UK Biobank (UKB), we performed gene-based association tests using exome sequencing data, as well as a genome-wide association study. We also constructed polygenic risk scores (PRS) in a subset of the cohort (Number of cases = 8231; Number of controls = 276,360) and calculated the impact on the prediction capacity of the PRS in a non-overlapping part of the cohort (Number of cases = 4342; Number of controls = 142,822). We generated additional PRSs that excluded the known causative variants.
We discovered and replicated a novel common variant (rs11604583) near the region where are located the TRIM51 and LRRC55 genes and identified a novel rare variant (rs187725533) located near the CREB3L1 gene, associated with 2.5-fold higher risk of DVT. In one of the PRS models constructed, the top decile of risk is associated with 3.4-fold increased risk, an effect that is 2.3-fold when excluding FVL carriers. In the top PRS decile, the cumulative risk of DVT at the age of 80 years is 10 % for FVL carriers, contraposed to 5 % for non-carriers. The population attributable fractions of having a high polygenic risk on the rate of DVT was estimated to be around 20 % in our cohort.
Individuals with a high polygenic risk of DVT, and not only carriers of well-studied variants such as FVL, may benefit from prevention strategies.
深静脉血栓形成(DVT)是一种复杂的疾病,其中 60%的风险是由遗传因素引起的,例如因子 V 莱顿(FVL)变体。DVT 要么没有症状,要么表现出非特异性症状,如果不进行治疗,DVT 会导致严重的并发症。其影响是巨大的,目前 DVT 预防仍存在研究空白。我们描述了遗传因素的贡献,并根据遗传构成对个体进行分层,以评估其是否有利于风险预测。
在英国生物库(UKB)中,我们使用外显子组测序数据进行基于基因的关联测试,以及全基因组关联研究。我们还在队列的一个子集(病例数=8231;对照组数=276360)中构建了多基因风险评分(PRS),并在队列的一个不重叠部分(病例数=4342;对照组数=142822)中计算了 PRS 对预测能力的影响。我们生成了排除已知致病变异的额外 PRS。
我们发现并复制了一个位于 TRIM51 和 LRRC55 基因区域附近的新的常见变异(rs11604583),并确定了一个位于 CREB3L1 基因附近的新的罕见变异(rs187725533),与 DVT 风险增加 2.5 倍相关。在构建的一个 PRS 模型中,风险最高的十分位数与风险增加 3.4 倍相关,当排除 FVL 携带者时,该效应增加 2.3 倍。在 PRS 最高十分位数中,80 岁时 DVT 的累积风险在 FVL 携带者中为 10%,而在非携带者中为 5%。我们的队列中,高多基因风险对 DVT 发生率的人群归因分数估计约为 20%。
患有 DVT 的高多基因风险的个体,不仅是像 FVL 这样研究充分的变异的携带者,可能受益于预防策略。